Argenx SE
Argenx SE was founded in 2008 and has its headquarters in Ghent, Belgium. It also has offices in the Netherlands, Japan, and the US. Argenx SE has a market capitalization of about $40 billion as of May 9, 2023, reflecting its strong growth potential and value creation for its shareholders
Argenx SE is committed to improving the lives of people suffering from severe autoimmune diseases and cancer by developing innovative antibody-based therapies. Argenx SE has a diverse and balanced pipeline of clinical and preclinical candidates, targeting novel and validated disease pathways. Some of its lead products include efgartigimod, cusatuzumab and ARGX-11.
The company has a robust pipeline of first-in-class antibodies in both early and late clinical stages of development, targeting various indications such as myasthenia gravis, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and acute myeloid leukemia. The company also has several partnered programs with leading pharmaceutical companies such as AbbVie, Janssen, and Zai Lab.
Argenx SE has received several awards and recognitions for its scientific excellence and business achievements. For example, in 2022, Argenx SE won the Scrip Award for Best Company in Europe, the Fierce Biotech Breakthrough Drug Award for efgartigimod, and the Belgian Biotech Award for Best Biotech Company. Argenx SE also ranked among the top 10 biotech companies in Europe by Labiotech. EU.
Foundation: 2008
Headquarters: Ghent, Belgium
Website: https://www.argenx.com/
